Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 441 to 450 of 890

TitleReference numberPublishedLast updated
Acalabrutinib for treating chronic lymphocytic leukaemiaTA689
Avelumab for untreated metastatic Merkel cell carcinomaTA691
Avelumab for treating metastatic Merkel cell carcinomaTA517
Anakinra for treating Still's diseaseTA685
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)TA686
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA687
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic diseaseTA684
Erenumab for preventing migraineTA682
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancerTA683
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myelomaTA680

Results per page

  1. 10
  2. 25
  3. 50
  4. All